

Correction: Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study

D. Gareth R. Evans^{1,2,3,4}, Roope A. Kallionpää⁵, Maurizio Clementi⁶, Eva Trevisson⁶, Victor-Felix Mautner⁷, Sacha J. Howell^{1,4,8}, Lauren Lewis², Ouidad Zehou⁹, Sirkku Peltonen¹⁰, Antonella Brunello¹¹, Elaine F. Harkness¹², Pierre Wolkenstein⁹ and Juha Peltonen⁵

Genetics in Medicine (2020) 22:242; <https://doi.org/10.1038/s41436-019-0671-2>

Correction to: *Genetics in Medicine* 2019; <https://doi.org/10.1038/s41436-019-0651-6>; published online 09 September 2019

In the original version of this Article, the affiliation details for Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy were incorrectly given as IOV, Oncology, Padova, Italy. This has now been corrected in both the PDF and HTML versions of the Article.



Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2019

¹The Christie NHS Foundation Trust, Manchester, UK; ²Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK; ³Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; ⁴Genesis Breast Cancer Prevention Centre and Nightingale Breast Screening Centre, University Hospital of South Manchester, Manchester Academic Health Science Centre, Manchester, UK; ⁵Institute of Biomedicine, University of Turku, Turku, Finland; ⁶Clinical Genetics Unit, Department of Women's and Children's Health, University of Padova, Padova, Italy; ⁷Phacomatoses Department, Department of Neurology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; ⁸Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; ⁹Referral Centre for Neurofibromatosis Dermatology, Hôpital Henri Mondor, APHP, UPEC, Créteil, France; ¹⁰Department of Dermatology, University of Turku and Turku University Hospital, Turku, Finland; ¹¹Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy; ¹²Division of Informatics, Imaging and Data Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. Correspondence: Juha Peltonen (juhpel@utu.fi)
These authors contributed equally: D. Gareth R. Evans, Roope A. Kallionpää

Published online: 8 October 2019